# A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer

Source: https://onco.cc/trials/nct04381130/  
OnCo record `nct04381130` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in pancreatic cancer, run by Everfront Biotech Co., Ltd., not yet recruiting.

## Summary

A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer is a phase 1/2, interventional study registered as NCT04381130 by Everfront Biotech Co., Ltd., with a registry enrolment figure of 30 participants, started 2027-04-01 and due to reach its primary completion in 2029-12-31. Interventions recorded: EF-009. Conditions listed: Pancreatic Cancer. Primary outcome: Maximum Tolerated Dose (MTD); Overall survival. Pancreatic eligibility wording from the registry: "Subject has cytological, histological, or pathological confirmation of pancreatic cancer Note: All histologic subtype(s) of exocrine and endocrine pancreatic cancer are eligible to enroll in the study". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT04381130
- Phase: 1/2
- Setting: A Phase I/IIa Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety and Efficacy Profile of EF-009 in Patients With Pancreatic Cancer
- Sponsor: Everfront Biotech Co., Ltd.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT04381130: https://clinicaltrials.gov/study/NCT04381130

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04381130.json